How should I manage a 40-year-old female with type 2 diabetes, recent diabetic ketoacidosis, A1c 13%, persistent hyperglycemia, hypertension at goal, hyperlipidemia, diabetic polyneuropathy, asthma, vitamin D deficiency, and reported non‑compliance?

Management of Severe Hyperglycemia with Recent DKA in Type 2 Diabetes

This patient requires immediate intensification to basal-bolus insulin therapy given her A1c of 13%, recent DKA hospitalization, and persistent severe hyperglycemia (glucose 535 mg/dL), regardless of adherence concerns. 1

Immediate Insulin Intensification

Your patient meets criteria for mandatory insulin therapy: A1c >10% (she has 13%), glucose ≥300 mg/dL (she had 535 mg/dL), and recent catabolic state (DKA). 1 The 2025 ADA Standards explicitly state insulin should be considered first when A1c >10% (>86 mmol/mol) or blood glucose ≥300 mg/dL. 1

Basal-Bolus Insulin Regimen

Start with total daily dose of 0.4-0.5 units/kg/day (approximately 26-32 units/day for her 64.68 kg weight). 2

• Basal insulin component: Initiate long-acting basal analog (glargine, detemir, or degludec) at 50% of total daily dose = 13-16 units once daily. 1, 2
• Prandial insulin component: Allocate remaining 50% divided across meals—start with 4-5 units of rapid-acting analog before each of her 1-2 meals per day. 1, 2

Titration protocol: Increase basal insulin by 2 units every 3 days until fasting glucose reaches goal without hypoglycemia. 1 For prandial insulin, increase by 1-2 units or 10-15% based on pre-meal and 2-hour postprandial readings. 1

Critical Safety Measures

Prescribe glucagon immediately for emergency hypoglycemia treatment, especially given the insulin intensification. 1, 2

Implement continuous glucose monitoring (CGM) or mandate SMBG at least 4-6 times daily to guide titration and prevent hypoglycemia during this aggressive insulin escalation. 2 CGM is now standard of care and particularly valuable for patients with adherence challenges as it provides real-time feedback. 2

Addressing "Non-Compliance"

Reframe this as barriers to care, not willful non-compliance. This patient has:

• Recent severe illness and hospitalization 3, 4
• Financial constraints (no insurance, delaying preventive care)
• Suboptimal nutrition (1-2 meals/day, admits unhealthy eating)
• Recent DKA indicating severe insulin deficiency 3, 5, 6

The recent DKA episode in a type 2 diabetic suggests either severe insulin deficiency or possible latent autoimmune diabetes (LADA)—her presentation warrants consideration that she may have more type 1-like physiology requiring insulin. 3, 5

Concurrent Medication Optimization

Continue metformin (if she's on it and eGFR >30 mL/min/1.73 m²) as it reduces cardiovascular mortality and is weight-neutral. 1 However, monitor vitamin B12 levels given her existing diabetic polyneuropathy, as metformin worsens B12 deficiency and neuropathy symptoms. 1

Add GLP-1 receptor agonist once glucose toxicity resolves and she obtains insurance. 1 When A1c is ≥1.5% above goal (she's 6% above a 7% goal), dual therapy is typically required. 1 GLP-1 RAs provide additional A1c lowering of 1-1.5%, weight loss benefit, and cardiovascular protection. 1

Immediate Diabetes Self-Management Education

Refer urgently to diabetes self-management education and support (DSMES) program—this is not optional. 2 She accepted nutritionist referral; ensure this happens within 1-2 weeks, not months. 2

Provide carbohydrate counting education and teach her to match prandial insulin to carbohydrate intake, even with irregular meal patterns. 2 Her 1-2 meals/day pattern requires flexible prandial dosing.

Blood Pressure and Lipid Management

Her BP of 128/64 mmHg is at goal (<130/80 mmHg for diabetes). 1 However, with diabetic polyneuropathy present, ensure she's on ACE inhibitor or ARB for renal protection if not already prescribed. 1

Address hyperlipidemia aggressively—she needs high-intensity statin therapy given diabetes plus neuropathy (indicating microvascular disease). 1

Vitamin D Supplementation

Treat her vitamin D deficiency, as deficiency correlates with worse glycemic control (inverse correlation with A1c, r = -0.19) and higher prevalence of neuropathy (50% in deficient patients). 7 While causality isn't proven, correction is low-risk and may improve outcomes. 7

Follow-Up Protocol

Recheck A1c in 3 months to evaluate response to intensive insulin therapy. 2 However, monitor glucose weekly via phone/portal to adjust insulin doses—don't wait 3 months to intensify further if needed. 1

Schedule visit in 1-2 weeks to review glucose logs, adjust insulin doses, assess for hypoglycemia, and reinforce education. 1, 2 This close follow-up is essential during insulin intensification.

Common Pitfalls to Avoid

Do not delay insulin intensification waiting for "better compliance"—the A1c of 13% and recent DKA indicate urgent need regardless of adherence. 1, 2 Glucose toxicity itself impairs insulin secretion and worsens hyperglycemia; treating aggressively can break this cycle. 1

Do not underdose insulin out of hypoglycemia fear—her current regimen is clearly insufficient. 1, 2 The risk of ongoing severe hyperglycemia (retinopathy, nephropathy progression, recurrent DKA) far exceeds hypoglycemia risk with proper monitoring. 3, 5, 6

Do not label her "non-compliant" in documentation—this creates bias in future care. 2 Document specific barriers (financial, nutritional, recent acute illness) and your interventions to address them. 2

Ensure uninterrupted access to insulin and supplies—work with social services, patient assistance programs, or provide samples if needed to prevent treatment gaps that precipitate DKA. 3 Her recent DKA during illness when she couldn't follow up illustrates this risk. 3, 4